A 52-year-old woman with disabling peripheral neuropathy: Review of diabetic polyneuropathy

JAMA

Volumn 302, Issue 13, 2009, Pages 1451-1458

  Rutkove, Seward B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATENOLOL; ATORVASTATIN; CARBAMAZEPINE; CITALOPRAM; CORTISONE; DULOXETINE; FLUOXETINE; FLUTICASONE; GABAPENTIN; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; LIDOCAINE; LISINOPRIL; METFORMIN; OXYCODONE; OXYCODONE PLUS PARACETAMOL; PAROXETINE; PHENYTOIN; PLACEBO; PRAMIPEXOLE; PREGABALIN; RANITIDINE; ROPINIROLE; THIOCTIC ACID; TOPIRAMATE; TRAMADOL; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOXIDANT;

ANOREXIA; ANXIETY; APPLICATION SITE ERYTHEMA; BABINSKI REFLEX; BEDTIME DOSAGE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FOOD AND DRUG ADMINISTRATION; GINGIVA HYPERPLASIA; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTERVERTEBRAL DISKECTOMY; LAMINECTOMY; LIVER TOXICITY; MUSCLE CRAMP; NAUSEA; NERVE CONDUCTION; NEUROPATHIC PAIN; NOTE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PLANTAR FASCIITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESTLESS LEGS SYNDROME; SENSITIVITY AND SPECIFICITY; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; SKIN BIOPSY; SKIN IRRITATION; SOMNOLENCE; SURAL NERVE; SWEATING; WEIGHT GAIN; XEROSTOMIA; ACUPUNCTURE; ARTICLE; BARIATRIC SURGERY; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; DECISION MAKING; DIAGNOSIS; FEMALE; GLYCEMIC INDEX; MASSAGE; MIDDLE AGED; PATHOPHYSIOLOGY;

ACUPUNCTURE THERAPY; ANALGESICS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; BARIATRIC SURGERY; DECISION MAKING; DIABETIC NEUROPATHIES; DIAGNOSIS, DIFFERENTIAL; ELECTROMYOGRAPHY; FEMALE; GLYCEMIC INDEX; HUMANS; MASSAGE; MIDDLE AGED;

EID: 70349910641     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1377     Document Type: Note

References (95)

1. Stamboulis E, Vassilopoulos D, Kalfakis N. Symptomatic focal mononeuropathies in diabetic patients. J Neurol. 2005;252(4):448-452.
2. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies. Muscle Nerve. 2002;25(4):477-491.
3. Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009; 73(1):39-45.
4. Genuth S, Alberti KG, Bennett P, et al; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-3167.
5. Smith AG, Singleton JR. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci. 2006;242(1-2):9-14. (Pubitemid 43295790)
6. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl) [in French]. Diabete Metab. 1977;3(4):245-256.
7. Pirart J. Diabetes mellitus and its degenerative complications (2nd part) (author's transl) [in French]. Diabete Metab. 1977;3(3):173-182.
8. Pirart J. Diabetes mellitus and its degenerative complications (author's transl) [in French]. Diabete Metab. 1977;3(2):97-107.
9. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors. Diabetologia. 1996;39(11):1377-1384.
10. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurology. 1993;43(4):817-824.
11. Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. Diabetes Care. 1997;20(3):322-329.
12. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003; 60(1):108-111. (Pubitemid 36070653)
13. Botez SA, Liu G, Logigian E, Herrmann DN. Is the bedside timed vibration test reliable? Muscle Nerve. 2009;39(2):221-223.
14. Richardson JK. The clinical identification of peripheral neuropathy among older persons. Arch Phys Med Rehabil. 2002;83(11):1553-1558. (Pubitemid 35304132)
15. Kwon OY, Minor SD, Maluf KS, Mueller MJ. Comparison of muscle activity during walking in subjects with and without diabetic neuropathy. Gait Posture. 2003;18(1):105-113. (Pubitemid 36814146)
16. Rutkove SB, Nardin RA, Raynor EM, Levy ML, Landrio MA. Lumbosacral radiculopathy mimicking distal polyneuropathy. J Clin Neuromuscul Dis. 2000; 2(2):65-69.
17. Liao KK, Chang MH, Wang S. Distal paresthesia in patients with cervical cord lesions. Zhonghua Yi Xue Za Zhi (Taipei). 1992;50(3):203-207.
18. Oh SJ, Meyer RD. Entrapment neuropathies of the tibial (posterior tibial) nerve. Neurol Clin. 1999;17(3):593-615. (Pubitemid 29337337)
19. Neufeld SK, Cerrato R. Plantar fasciitis: evaluation and treatment. J Am Acad Orthop Surg. 2008;16(6):338-346.
20. Rosenbaum R. Neuromuscular complications of connective tissue diseases. Muscle Nerve. 2001;24(2):154-169. (Pubitemid 32105813)
21. Pirzada NA, Morgenlander JC. Peripheral neuropathy in patients with chronic renal failure. Postgrad Med. 1997;102(4):249-250.
22. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy [published online ahead of print July 21, 2009]. Curr Opin Neurol. doi:10.1097/WCO .0b013e3282ef79e3.
23. Goldman AL, Braman SS. Isoniazid: a review with emphasis on adverse effects. Chest. 1972;62(1):71-77.
24. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17.
25. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445-448.
26. Law M, Rudnicka AR. Statin safety. Am J Cardiol. 2006;97(8A):52C-60C.
27. Gorson KC, Ropper AH. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry. 2006;77(3):354-358. (Pubitemid 43295158)
28. Perkins BA, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods. Clin Neurophysiol. 2003;114(7):1167-1175. (Pubitemid 36776813)
29. England JD, Gronseth GS, Franklin G, et al; American Academy of Neurology. Evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Neurology. 2009;72(2): 177-184.
30. Diem P, Laederach-Hofmann K, Navarro X, Mueller B, Kennedy WR, Robertson RP. Diagnosis of diabetic autonomic neuropathy. Eur J Clin Invest. 2003;33 (8):693-697.
31. Polydefkis M, Hauer P, Griffin JW, McArthur JC. Skin biopsy as a tool to assess distal small fiber innervation in diabetic neuropathy. Diabetes Technol Ther. 2001;3(1):23-28. (Pubitemid 32405674)
32. Ruth A, Schulmeyer FJ, Roesch M, Woertgen C, Brawanski A. Diagnostic and therapeutic value due to suspected diagnosis, long-term complications, and indication for sural nerve biopsy. Clin Neurol Neurosurg. 2005;107(3):214-217. (Pubitemid 40502227)
33. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008; 9(4):301-314.
34. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev. 2006;22(4):257-273.
35. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288(20):2579-2588.
36. Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol. 2002;50:205-228.
37. Genuth S. Insights from the Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12(suppl 1):34-41. (Pubitemid 44963609)
38. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9(1):14-36. (Pubitemid 351201678)
39. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55(6):498-510. (Pubitemid 46962309)
40. Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982; 5(4):386-390. (Pubitemid 12093554)
41. White NH, Waltman SR, Krupin T, Santiago JV. Reversal of neuropathic and gastrointestinal complications related to diabetes mellitus in adolescents with improved metabolic control. J Pediatr. 1981;99(1):41-45. (Pubitemid 11046415)
42. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(4)(suppl):S12-S25.
43. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5(3):143-149. (Pubitemid 38879392)
44. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454.
45. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311(7012):1047-1052.
46. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20(6):449-458. (Pubitemid 30948740)
47. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain. Pain. 1999;83(3):389-400.
48. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain. Pain. 2003;105(1-2):71-78.
49. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid. Diabet Med. 2004;21(2):114-121. (Pubitemid 38221809)
50. Tang J, Wingerchuk DM, Crum BA, Rubin DI, Demaerschalk BM. Alphalipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007; 13(3):164-167. (Pubitemid 46743087)
51. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998; 50(6):1842-1846. (Pubitemid 28283262)
52. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy. Diabetes Care. 2008; 31(7):1448-1454.
53. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity. Med Res Rev. 1999;19(2):149-177. (Pubitemid 29124983)
54. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105(1-2):133-141.
55. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. Med Gen Med. 2007;9(2):36. (Pubitemid 46805366)
56. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy. Pain. 2004;110(3):697-706.
57. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain. Clin Ther. 2007;29(suppl):2536-2546.
58. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007; 30(1):21-26. (Pubitemid 46052495)
59. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328(7446):991. (Pubitemid 38530371)
60. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-118. (Pubitemid 40828506)
61. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8): 1411-1420. (Pubitemid 44632065)
62. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250-1256.
63. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy. BMJ. 2007;335(7610):87.
64. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy. Neurology. 2003;60(6):927-934.
65. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-1836. (Pubitemid 28544423)
66. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159(16): 1931-1937.
67. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001; 57(3):505-509. (Pubitemid 32757601)
68. Raskin P, Donofrio PD, Rosenthal NR, et al; CAPSS-141 Study Group. Topiramate vs placebo in painful diabetic neuropathy. Neurology. 2004;63(5):865-873. (Pubitemid 39297649)
69. Thienel U, Neto W, Schwabe SK, Vijapurkar U; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy. Acta Neurol Scand. 2004;110(4):221-231. (Pubitemid 39274056)
70. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16(12):1040-1043. (Pubitemid 30051432)
71. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care. 1992;15(2):159-165.
72. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61(6):914-918. (Pubitemid 38747332)
73. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes. Pain. 2003;106(1-2): 151-158.
74. Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc. 1999;89(9):468-471.
75. Sima AA, Calvani M, Mehra M, Amato A; Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005;28(1):89-94.
76. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray. Diabetes Care. 2002;25(10):1699- 1703.
77. Cohen KL, Harris S. Efficacy and safety of nonsteroidal antiinflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med. 1987;147(8):1442-1444. (Pubitemid 17122120)
78. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care. 1997;20(11):1702- 1705. (Pubitemid 27463046)
79. Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy. Diabetes Res Clin Pract. 1998;39(2): 115-121. (Pubitemid 28228444)
80. Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? Diabetes Care. 2008;31(2):316-321.
81. Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand. 2004;48(3): 328-336. (Pubitemid 38295345)
82. Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy. Clin Ther. 2006;28(10):1607-1618.
83. Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2008; (3):CD006152.
84. Benatar M, Chapman KM, Rutkove SB. Repetitive nerve stimulation for the evaluation of peripheral nerve hyperexcitability. J Neurol Sci. 2004;221(1-2): 47-52. (Pubitemid 38721290)
85. Miller TM, Layzer RB. Muscle cramps. Muscle Nerve. 2005;32(4):431-442.
86. Diener HC, Dethlefsen U, Dethlefsen-Gruber S, Verbeek P. Effectiveness of quinine in treating muscle cramps. Int J Clin Pract. 2002;56(4):243-246.
87. Tahmoush AJ, Alonso RJ, Tahmoush GP, Heiman-Patterson TD. Cramp-fasciculation syndrome: a treatable hyperexcitable peripheral nerve disorder. Neurology. 1991;41(7):1021-1024.
88. Rutkove SB, Matheson JK, Logigian EL. Restless legs syndrome in patients with polyneuropathy. Muscle Nerve. 1996;19(5):670-672. (Pubitemid 26120181)
89. Gemignani F, Brindani F, Vitetta F, Marbini A, Calzetti S. Restless legs syndrome in diabetic neuropathy. J Peripher Nerv Syst. 2007;12(1):50-53.
90. Ferini-Strambi L. Treatment options for restless legs syndrome. Expert Opin Pharmacother. 2009;10(4):545-554.
91. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. (Pubitemid 36159355)
92. Boulton AJ, Vinik AI, Arezzo JC, et al; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-962.
93. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29(suppl): 2477-2497. (Pubitemid 350299458)
94. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001; 429(1-3):23-37.
95. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? Int J Clin Pract. 2006;60(11):1471-1483. (Pubitemid 44560348)